与晚期乳腺癌患者的疗效和毒性相关的Palbociclib暴露
S M Buijs1, M I Mohmaed Ali2, E Oomen-de Hoop1
1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ESMO open
|February 15, 2025
概括
较高的palbociclib暴露不会影响乳腺癌患者的无进展生存率. 然而,增加暴露与剂量减少相关,表明这些可以管理毒性.
科学领域:
- 在瘤学瘤学.
- 药理动力学 药理动力学
- 临床试验 临床试验
背景情况:
- 有限的数据存在于对林依赖性激酶4/6抑制剂 (CDK4/6i) 的暴露反应和暴露毒性.
- 了解这些关系对于优化乳腺癌中CDK4/6i治疗至关重要.
研究的目的:
- 调查palbociclib暴露与无进展生存时间 (PFS) 之间的关联.
- 检查palbociclib暴露与不良事件 (AE) 和剂量减少之间的关系.
主要方法:
- 分析了前性多中心SONIA试验中344名患者的药理动力学 (PK) 数据.
- 人口PK建模被用于确定个人palbociclib暴露 (深度度和AUC).
- 考克斯回归和奇平方试验评估了palbociclib暴露,PFS,AE和剂量减少之间的关联.
主要成果:
- 在palbociclib暴露和PFS之间没有发现显著的关联.
- 较高的palbociclib暴露与治疗期间剂量减少的增加有关.
- 在前3个月内没有观察到3-4级AE的发病率增加,而帕尔博西克利布的暴露率更高.
结论:
- 在晚期乳腺癌患者中,Palbociclib暴露似乎没有影响PFS.
- 剂量减少可以安全地实施,以管理与palbociclib相关的毒性.
- 对CDK4/6i的暴露导向剂量策略进行进一步的研究是有必要的.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
112
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
112
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:21Drugs for Treatment of Constipation-Predominant IBS
129
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
129
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K